Executive Intelligence

Andrew Feinberg

Founder

Andrew Feinberg is listed as a founder of BostonGene based in United States on Brel Digital’s verified company intelligence record.

In this profile

Quick Facts

  • Role Founder
  • Company BostonGene
  • Country United States
  • Industry AI in Healthcare
  • Founded 2015
  • Known For BostonGene represents biopharma's shift toward biologically grounded AI foundation models for trial design and patient selection…
  • Status Active
  • Last Reviewed Jul 2026

Executive Summary

Andrew Feinberg appears in Brel Digital’s verified company_founders attribution for BostonGene based in United States in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted. Company context (from the verified BostonGene profile): Waltham biotechnology company applying an AI foundation model of tumor and immune biology to precision oncology and drug development Why the company matters (verified company field): BostonGene represents biopharma's shift toward biologically grounded AI foundation models for trial design and patient selection — its 2026 Frost & Sullivan recognition and CEO Andrew Feinberg's cross-industry AI governance visibility reflect oncology AI maturing into enterprise decision infrastructure. Official company website on file: https://www.bostongene.com. Readers should consult that site and the Sources section for primary evidence. Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Career Timeline

Verified company milestones linked to this executive’s organization.

  1. 2015 Company founded

    BostonGene was founded in 2015 per the company profile source on file.

    Source
  2. 2015 Development

    2015: BostonGene founded in Waltham, Massachusetts.

    Source
  3. 2026 Development

    2026: BostonGene received Frost & Sullivan 2026 Global Company of the Year for AI-driven multimodal oncology platforms.

    Source
  4. 2026 Leadership

    February 2026: CEO Andrew Feinberg scheduled to keynote Mobile World Congress Barcelona on governing AI at scale.

    Source

Connected Company

Connected Products

Connected Reports

Connected Insights

Industry Intelligence

Andrew Feinberg appears in Brel Digital’s verified company_founders attribution for BostonGene based in United States in the Healthcare sector. This profile records that founder relationship using sources already on file for the company. Personal biography details that are not evidenced in those sources are omitted.

Company context (from the verified BostonGene profile): Waltham biotechnology company applying an AI foundation model of tumor and immune biology to precision oncology and drug development

Why the company matters (verified company field): BostonGene represents biopharma's shift toward biologically grounded AI foundation models for trial design and patient selection — its 2026 Frost & Sullivan recognition and CEO Andrew Feinberg's cross-industry AI governance visibility reflect oncology AI maturing into enterprise decision infrastructure.

Official company website on file: https://www.bostongene.com. Readers should consult that site and the Sources section for primary evidence.

Brel Digital does not invent prior roles, education, funding history, or awards for founder profiles. Where additional verified public leadership pages become available, this profile should be deepened in a subsequent editorial review.

Sources and references

This article draws on publicly available company information, official websites, filings, interviews, announcements, and other cited sources. Information may change over time.

The AI Brief

Founder and company intelligence, weekly.

Subscribe